NCT05730218已完成2 期
A Phase 2, Randomized, Sham-Controlled, Single-Masked, Dose-Ranging, Multi-Center Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Macula-off Rhegmatogenous Retinal Detachment
ONL Therapeutics35 个研究点 分布在 1 个国家目标入组 136 人开始时间: 2023年4月4日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 136
- 试验地点
- 35
- 主要终点
- Mean area under the log contrast sensitivity function (AULCSF)
研究概览
简要总结
The goal of this Phase 2 clinical trial is to learn about ONL1204 Ophthalmic Solution in terms of safety and how well the drug works in patients that have a macula-off (central point of vision) rhegmatogenous retinal detachment (RRD). The main questions it aims to answer are:
- Does ONL1204 improve vision in macula-off RRD patients when used before retinal detachment repair surgery compared to patients that have surgery alone?
- Is ONL1204 safe to use as an add-on drug before retinal repair surgery?
Researchers will observe patients that receive two different dosages of ONL1204 Ophthalmic Solution (50 µg or 200 µg) compared to current standard therapy (no treatment) to see if there are differences in vision and safety outcomes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult subject, ≥18 years old at the time of informed consent
- •Able and willing to give informed consent and comply with all study visits and procedures
- •Presentation with macula-off RRD with a duration ≥24 hours up to 14 days from time of central visual decline to the Baseline (Visit 2) visit, inclusive (based on subject reported date of loss of central vision) in the Study Eye (SE)
- •Visual acuity with subject's current corrective lenses or pinhole of 20/100 (line scoring) on the Snellen or ETDRS chart to light perception (LP) in the SE
- •Visual acuity with subject's current corrective lenses or pinhole of 20/200 (line scoring) or better in the fellow eye
- •Determination by Investigator of macula-off status by clinical examination with confirmation by SD-OCT or B-scan ultrasound, if available.
- •SOC retinal reattachment surgery by means of a pars plana vitrectomy (with or without scleral buckle) is indicated
- •In the opinion of the Investigator, can safely undergo the IVT injection procedure at Baseline (Visit 2)
- •Surgical repair scheduled or anticipated to take place >12 hours after IVT injection or sham (Visit 2) and ≤10 days from Screening (Visit 1)
排除标准
- •Presence of a complex retinal detachment (RD) in the SE, identified by one or more of the following:
- •Giant retinal tear, defined as retinal break ≥3 clock hours in extent
- •Proliferative vitreoretinopathy grade C1 or worse on the Retina Society Terminology Committee Classification System
- •Presence of tractional detachments as seen in proliferative retinopathies
- •RRD in the setting of open- or closed-globe trauma
- •RRD following endophthalmitis or infectious retinitis
- •Similarly complex RD as determined by the Investigator
- •Use of silicone oil tamponade in the primary RD repair without planned removal by end of study
- •Vitreous hemorrhage or cataract in the SE that prohibits adequate examination for other exclusion criteria, per Investigator's discretion
- •Presence of ocular or periocular infection or intraocular inflammation in either eye
- •Uncontrolled glaucoma, as defined by an IOP >36 mmHg in either eye, at Screening
- •Any other significant ocular disease in the SE that, in the opinion of the Investigator, would preclude a postoperative (post-op) visual acuity of at least 20/30
- •History of previous ocular surgery in the SE for RD (excluding only barrier laser), endophthalmitis, glaucoma tube shunts, trabeculectomy, or ocular trauma
- •Any systemic condition or ocular condition in either eye that, in the opinion of the Investigator, makes the subject unsuitable for treatment with an investigational agent or that would compromise the safety and tolerability of assessments in the trial
- •History of and/or active:
- •Autoimmune disease in active flare (i.e., not well controlled on current medications) with ocular involvement that, in the opinion of the Investigator, would impact ability to participate in the trial and/or alter the outcome of retinal reattachment surgery
- •Ocular malignancy
- •Proliferative diabetic retinopathy or diabetic macular edema or uveitis
- •Currently participating in other clinical trials or use of any other investigational drugs or devices within 12 weeks prior to Visit 1
- •Females who are pregnant or lactating, and women of childbearing potential (WOCBP) or men with female partners of childbearing potential who are not using at least one adequate contraceptive precaution (e.g., intrauterine device, oral contraceptive, barrier method, or other contraception deemed adequate by the Investigator)
研究组 & 干预措施
Treatment Group A
Experimental
ONL1204 Ophthalmic Solution Dose A administered by intravitreal injection
干预措施: ONL1204 Ophthalmic Solution (Drug)
Treatment Group B
Experimental
ONL1204 Ophthalmic Solution Dose B administered by intravitreal injection
干预措施: ONL1204 Ophthalmic Solution (Drug)
Treatment Group C
Sham Comparator
Sham injection is performed by touching the eye surface with a syringe without a needle
干预措施: Sham treatment (Drug)
结局指标
主要结局
Mean area under the log contrast sensitivity function (AULCSF)
时间窗: Week 24
Mean AULCSF as measured with the Adaptive Sensory Technology (AST) Manifold Contrast Vision Meter at Week 24 for subjects who do not have primary surgical failure.
次要结局
- Mean best-corrected visual acuity (BCVA) measured in logarithm of the minimum angle of resolution (logMAR)(Week 12)
- AULCSF(Week 12)
- BCVA(Week 24)
研究者
研究点 (35)
Loading locations...
相似试验
已完成
1 期
A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle GlaucomaOpen Angle GlaucomaNCT05160805ONL Therapeutics25
已完成
2 期
RMP-A03 Ocular Suspension in Patients With PterygiumPterygiumNCT05794204Suzhou Raymon Pharmaceuticals Company, Ltd.77
已完成
2 期
Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With PresbyopiaPresbyopiaNCT05665387Santen Inc.79
撤回
2 期
OSIG-eye Drops Treatment for Dry Eye DiseaseDry EyeNCT04510428University of Illinois at Chicago
已完成
2 期
A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye DiseaseDry Eye DiseaseNCT05238597Aramis Biosciences, Inc.207